ABT vs AEP Stock Comparison

Scores Breakdown

Metric	ABT	AEP
📈 Growth	22/30	22/30
💰 Profitability	17/20	16/20
🏦 Financial Health	15/20	12/20
💵 Valuation	12/20	14/20
⚠️ Risk (lower is better)	4/10	7/10
Overall Score	72/100	67/100

Side-by-Side Summaries

ABT Analysis	AEP Analysis
📈 Growth & Financial Trajectory Over the 8-quarter window, Revenue gravitated around $9.96B to $11.16B, ending at $11.16B in 2026 Q1, a start-to-end rise of about $1.2B (~12%). Net income remained positive through most quarters, with modest-to-strong fluctuations; several quarters show mid-single-digit billions in income, with notable variability from one-off items (e.g., tax effects). 💰 Margins & Cash Flow Gross Margin was solid, around 56% on average (Gross Profit ~6.3B vs Revenues ~11.2B in 2026 Q1). Operating margin ranged roughly from 12% to 18%, peaking in 2025 Q2. Net cash flow from operating activities was consistently positive (e.g., 2026 Q1: $1.315B; prior quarters in the 1.4–2.9B range), while investing activities were typically cash outflows and financing modest. 🛡️ Balance Sheet & Liquidity Total assets approximate $72B–$110B over the period with equity in the low-to-mid $50B range. The company shows a healthy current ratio (~~1.3–1.5) and modest long-term debt (~~$14–19B), supporting liquidity and balance sheet resilience. ⚠️ Key Drivers & Risks Drivers: (1) Pharma/medical devices demand; (2) diversified product mix and recurring revenue from Rx/OTC portfolios. Risks: (1) Regulatory/tax volatility and pricing pressure; (2) macro-cycle sensitivity and currency exposure.	📈 Growth & Financial Trajectory The eight quarters show revenue rising from $5.420B in 2024 Q3 to $6.020B in 2026 Q1, about a net increase of ~11%. Net income fluctuated: from $0.962B at the start to $0.903B at the end, with a peak near $1.288B in 2025 Q2. This signals a healthier top line with episodic earnings swings, ending with higher revenue but a slightly lower cumulative net income than the start. 💰 Margins & Cash Flow Net income margins averaged in the mid-teens, with notable strength around 25% in 2025 Q2. Operating cash flow tended to be positive across quarters, while investing cash flow was typically negative, reflecting ongoing capex. Cash flow from operations generally ranged in the low-to-mid billions, with an indicative average near $1.8B and occasional peaks near $2.5B. 🛡️ Balance Sheet & Liquidity Assets sit in the $110B–$118B range, with liabilities around $76B–$85B and equity roughly $27B–$33B; end-quarter figures show long-term debt near $42B–$50B. The regulated utility profile supports resilience, though leverage remains notable for the sector. ⚠️ Key Drivers & Risks Drivers: regulated rate recovery and ongoing grid modernization investments. Risks: interest-rate sensitivity and regulatory/legislative shifts; earnings volatility driven by weather and macro cycles may affect valuation.

ABT Analysis

AEP Analysis

📈 Growth & Financial Trajectory

Over the 8-quarter window, Revenue gravitated around $9.96B to $11.16B, ending at $11.16B in 2026 Q1, a start-to-end rise of about $1.2B (~12%). Net income remained positive through most quarters, with modest-to-strong fluctuations; several quarters show mid-single-digit billions in income, with notable variability from one-off items (e.g., tax effects).

💰 Margins & Cash Flow

Gross Margin was solid, around 56% on average (Gross Profit ~6.3B vs Revenues ~11.2B in 2026 Q1). Operating margin ranged roughly from 12% to 18%, peaking in 2025 Q2. Net cash flow from operating activities was consistently positive (e.g., 2026 Q1: $1.315B; prior quarters in the 1.4–2.9B range), while investing activities were typically cash outflows and financing modest.

🛡️ Balance Sheet & Liquidity

Total assets approximate $72B–$110B over the period with equity in the low-to-mid $50B range. The company shows a healthy current ratio (~~1.3–1.5) and modest long-term debt (~~$14–19B), supporting liquidity and balance sheet resilience.

⚠️ Key Drivers & Risks

Drivers: (1) Pharma/medical devices demand; (2) diversified product mix and recurring revenue from Rx/OTC portfolios.
Risks: (1) Regulatory/tax volatility and pricing pressure; (2) macro-cycle sensitivity and currency exposure.

📈 Growth & Financial Trajectory

The eight quarters show revenue rising from $5.420B in 2024 Q3 to $6.020B in 2026 Q1, about a net increase of ~11%. Net income fluctuated: from $0.962B at the start to $0.903B at the end, with a peak near $1.288B in 2025 Q2. This signals a healthier top line with episodic earnings swings, ending with higher revenue but a slightly lower cumulative net income than the start.

💰 Margins & Cash Flow

Net income margins averaged in the mid-teens, with notable strength around 25% in 2025 Q2. Operating cash flow tended to be positive across quarters, while investing cash flow was typically negative, reflecting ongoing capex. Cash flow from operations generally ranged in the low-to-mid billions, with an indicative average near $1.8B and occasional peaks near $2.5B.

🛡️ Balance Sheet & Liquidity

Assets sit in the $110B–$118B range, with liabilities around $76B–$85B and equity roughly $27B–$33B; end-quarter figures show long-term debt near $42B–$50B. The regulated utility profile supports resilience, though leverage remains notable for the sector.

⚠️ Key Drivers & Risks

Drivers: regulated rate recovery and ongoing grid modernization investments.
Risks: interest-rate sensitivity and regulatory/legislative shifts; earnings volatility driven by weather and macro cycles may affect valuation.

Similar Companies

ABBV Score: 59 BSX Score: 81 ELV Score: 77 ISRG Score: 85 JNJ Score: 79 MDT Score: 67 TMO Score: 75 TSLA Score: 62

Top Rated Companies

View Top 20 →

MU "MICRON TECHNOLOGY INC"

AVGO "Broadcom Inc."

KMI "KINDER MORGAN, INC."

MNST "Monster Beverage Corp"

NEM "NEWMONT Corp /DE/"